Aurinia Pharmaceuticals Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Aurinia Pharmaceuticals Inc. (AUPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $14.62 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $13.98, a 84.92% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $7.56, a 6.18% increase year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.12, a 19.46% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.84, a 26.33% decline year-over-year.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $7.83, a 18.10% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $6.63, a 30.43% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $9.53, a 99.91% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $11140.00, a 22.85% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $14.62 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $13.98 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $7.83 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $7.72 10-Q · filed 2025-11-04 | ||||
| 2025-06-30 | $7.61 10-Q · filed 2025-07-31 | ||||
| 2025-03-31 | $7.56 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $6.63 10-K · filed 2025-02-27 | ||||
| 2024-09-30 | $5.89 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $6.00 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $7.12 10-Q · filed 2024-05-02 | ||||
| 2023-12-31 | $9.53 10-K · filed 2024-02-15 | ||||
| 2023-09-30 | $9.68 10-Q · filed 2023-11-02 | ||||
| 2023-06-30 | $9.78 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $8.84 10-Q · filed 2023-05-04 | ||||
| 2022-12-31 | $11140.00 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | $11.25 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $11.96 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $12.00 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $14440.00 10-K · filed 2022-02-28 | ||||
| 2020-12-31 | $15.61 10-K · filed 2022-02-28 | $15610.00 10-K · filed 2021-02-24 | |||
| 2019-12-31 | $6.00 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $5.29 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |